Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4045032 | 0.87 | SMN1; SMN2 (0.36) | PRKCZALDH1A1 | |
| SCHEMBL4043225 | 0.86 | CD274 (0.34) | PRKCZ | |
| SCHEMBL4044214 | 0.83 | MAPT (0.43) | FGFR1ALDH1A1 | |
| SCHEMBL4039070 | 0.82 | CYP11B2 (0.39) | ALDH1A1 | |
| SCHEMBL4041484 | 0.81 | EGLN1 (0.37) | ALDH1A1 | |
| SCHEMBL4042657 | 0.81 | NPC1 (0.41) | — | |
| SCHEMBL4042421 | 0.80 | CD274 (0.40) | FGFR1ALDH1A1 | |
| SCHEMBL27598064 | 0.79 | FGFR1 (0.36) | FGFR1METAP1PRKCZALDH1A1 | |
| SCHEMBL4041718 | 0.79 | DRD3 (0.33) | — | |
| SCHEMBL4043691 | 0.78 | HTR2C (0.32) | PRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1319659-B1 | TRIAZINONES AND MEDICINAL USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-03-11 | — | — | EP | claimed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | claimed |
| EP-1319659-B1 | TRIAZINONES AND MEDICINAL USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | GRIK1, GRIK3, GRIK2 | FGFR1 798/4885METAP1 3890/4885PRKCZ 1577/4885 |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | GRIK3, GRIK1, GRIK2 | FGFR1 1031/4885METAP1 4162/4885PRKCZ 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.